Edenbridge Pharmaceuticals LLC has received FDA approval for its ANDA219819 application for Nintedanib Esyslate tablets, strengthening the firm’s portfolio with the generic version of the brand drug. While the April 2026 launch date does not impact current revenue, market analysts anticipate a potentially significant opportunity to capture market share in the specific therapeutic area once the patent cliff renders the branded treatment fully interchangeable.